Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$10.58 - $17.9 $226,528 - $383,256
21,411 Added 5420.51%
21,806 $237 Million
Q1 2024

May 15, 2024

BUY
$18.62 - $26.95 $7,354 - $10,645
395 New
395 $7.4 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $292M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Point72 Asia (Singapore) Pte. Ltd. Portfolio

Follow Point72 Asia (Singapore) Pte. Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asia (Singapore) Pte. Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asia (Singapore) Pte. Ltd. with notifications on news.